New combo pill showdown: which diabetes cocktail wins?

NCT ID NCT07442006

Recruiting now Disease control Sponsor: JW Pharmaceutical Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests four different drug combinations in 178 adults with type 2 diabetes whose blood sugar is not well controlled on metformin and an SGLT-2 inhibitor. Over 12 weeks, researchers will measure how much and how often blood sugar swings. The goal is to find which combo offers the steadiest glucose levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Empagliflozin/Metformin, Anagliptin, Metformin, Empagliflozin/Linagliptin
What this could lead to: If successful, this could show which drug combination best stabilizes blood sugar and improves daily glucose control for people with type 2 diabetes.
What could go wrong: This is a mid-stage trial with only 178 participants over 12 weeks, so results may not apply to everyone. Side effects like kidney issues or metabolic acidosis are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS (T2DM)

Contacts and locations

Locations

The Catholic University of Korea, Bucheon St. Mary's Hospital, Principal Investigator
RECRUITING

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.